CymaBay Therapeutics, Inc.

NASDAQ:CBAY

32.48 (USD) • At close March 21, 2024
Bedrijfsnaam CymaBay Therapeutics, Inc.
Symbool CBAY
Munteenheid USD
Prijs 32.48
Beurswaarde 3,728,216,800
Dividendpercentage 0%
52-weken bereik 7.261 - 32.5
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sujal A. Shah
Website https://www.cymabay.com

An error occurred while fetching data.

Over CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis

Vergelijkbare Aandelen

Mainz Biomed B.V. logo

Mainz Biomed B.V.

MYNZ

5 USD

Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc.

ALDX

5.025 USD

Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

MIST

1.97 USD

Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc.

CODX

0.744 USD

Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc.

RYTM

53.66 USD

Beyond Air, Inc. logo

Beyond Air, Inc.

XAIR

0.359 USD

Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals Inc.

FUSN

21.55 USD

Omeros Corporation logo

Omeros Corporation

OMER

8.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)